A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Tulpule, A [1 ]
Khan, AU [1 ]
Mohrbacher, AF [1 ]
Espina, BM [1 ]
Buchanan, L [1 ]
Berman, N [1 ]
Gorospe, G [1 ]
Boswell, WD [1 ]
Nathwani, BN [1 ]
Levine, AM [1 ]
机构：
[1] USC, Keck Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6688
引用
收藏
页码：604S / 604S
页数：1
相关论文
共 50 条
  • [31] A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    LeBlanc, Michael
    Farnsworth, Brent
    Iannone, Maria
    Glenn, Martha J.
    Fisher, Richard I.
    Miller, Thomas P.
    BLOOD, 2012, 120 (06) : 1210 - 1217
  • [32] Liposomal doxorubicin in combination with vincristine, cyclophosphamide and prednisone in patients with aggressive diffuse large B-cell lymphomas (DLBCL)
    Stulginskaya, Marina A.
    Dudnichenko, Alexander S.
    ANNALS OF ONCOLOGY, 2004, 15 : 155 - 156
  • [33] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With or Without Rituximab as First-Line Therapy for Aggressive Non-Hodgkin Lymphoma
    Lamar, Zanetta S.
    Fino, Nora
    Palmer, Jodi
    Gruber, Lindsey
    Morris, Bonny B.
    Raetskaya-Solntseva, Olga
    Kennedy, LeAnne
    Vaidya, Rakhee
    Hurd, David
    Zamkoff, Kenneth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (02) : 76 - 81
  • [34] Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)
    Younes, Anas
    Flinn, Ian
    Berdeja, Jesus G.
    Friedberg, Jonathan W.
    Alberti, Sara
    Thieblemont, Catherine
    Morschhauser, Franck
    Hellemans, Peter
    Hall, Brett
    Smit, Johan
    Skee, Donna
    de Vries, Ronald
    Todorovic, Marija
    Khan, Imran
    Fourneau, Nele
    Oki, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index
    Aydin, F
    Ulusoy, S
    Ovali, E
    JOURNAL OF CHEMOTHERAPY, 1997, 9 (06) : 446 - 451
  • [36] A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma
    Torka, Pallawi
    Patel, Priyank
    Tan, Wei
    Wilding, Gregory
    Bhat, Seema A.
    Czuczman, Myron S.
    Lee, Kelvin P.
    Deeb, George
    Neppalli, Vishala
    Mavis, Cory
    Wallace, Paul
    Hernandez-Ilizaliturri, Francisco J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) : E51 - E60
  • [37] Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
    Hagemeister, Fredrick
    Rodriguez, Maria Alma
    Deitcher, Steven R.
    Younes, Anas
    Fayad, Luis
    Goy, Andre
    Dang, Nam H.
    Forman, Arthur
    McLaughlin, Peter
    Medeiros, Leonard Jeffrey
    Pro, Barbara
    Romaguera, Jorge
    Samaniego, Felipe
    Silverman, Jeffrey A.
    Sarris, Andreas
    Cabanillas, Fernando
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (05) : 631 - 638
  • [38] EFFICACY OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN ELDERLY PATIENTS WITH AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A MULTICENTRIC STUDY
    Loscocco, F.
    Isidori, A.
    Ferrara, F.
    Merli, F.
    Ilariucci, F.
    Falorio, S.
    Angrilli, F.
    Fioritoni, G.
    Alesiani, F.
    Pollio, F.
    Celentano, M.
    Cangini, D.
    Musuraca, G.
    Catarini, M.
    Giglio, G.
    Vallisa, D.
    Arcari, A.
    Paolini, R.
    Guiducci, B.
    Ricciardi, T.
    Rocchi, M.
    Picardi, P.
    Visani, G.
    HAEMATOLOGICA, 2013, 98 : 135 - 135
  • [39] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
    Candelaria, Myrna
    Duenas-Gonzalez, Alfonso
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [40] Reduced dose of non-pegylated liposomal doxorrubicin with cyclophosphamide, vincristine and prednisone ± rituximab for elderly patients with aggressive lymphoma non candidates to standard chemotherapy
    Gimeno, Eva
    Alvarez, Alberto
    Pedro, Carme
    Abella, Eugenia
    Gomez, Miquel
    Comin, Josep
    Besses, Carles
    Salar, Antonio
    BLOOD, 2007, 110 (11) : 186B - 186B
12345